Puma Biotechnology - Public Comps and Valuation Multiples

Puma Biotechnology Overview

About Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Founded

2007

HQ

Employees

172

Website

pumabiotechnology.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $220M

Last FY EBITDA $48.1M

EV

$219M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Puma Biotechnology Financials

As of September 2025, Puma Biotechnology reported last 12-month revenue of $220M.

In the same period, Puma Biotechnology generated $167M in LTM gross profit and $28.4M in net income.

See Puma Biotechnology valuation multiples based on analyst estimates

Puma Biotechnology P&L

In the most recent fiscal year, Puma Biotechnology reported revenue of $230M and EBITDA of $48.1M.

Puma Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Puma Biotechnology valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$220M	XXX	$230M	XXX	XXX	XXX
Gross Profit	$167M	XXX	$166M	XXX	XXX	XXX
Gross Margin	76%	XXX	72%	XXX	XXX	XXX
EBITDA	n/a	XXX	$48.1M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	21%	XXX	XXX	XXX
EBIT	$32.4M	XXX	$31.0M	XXX	XXX	XXX
EBIT Margin	15%	XXX	13%	XXX	XXX	XXX
Net Profit	$28.4M	XXX	$30.3M	XXX	XXX	XXX
Net Margin	13%	XXX	13%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Puma Biotechnology including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $220M. In the most recent fiscal year, Puma Biotechnology achieved $230M in revenue and $48.1M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$220M	Analyst estimates available to subscribers	$230M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$167M	Analyst estimates available to subscribers	$166M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	76.1% gross margin	Analyst estimates available to subscribers	72.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$48.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	20.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$32.4M	Analyst estimates available to subscribers	$31.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	14.8% EBIT margin	Analyst estimates available to subscribers	13.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$28.4M	Analyst estimates available to subscribers	$30.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.9% net profit margin	Analyst estimates available to subscribers	13.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Puma Biotechnology

This financial data table provides comprehensive performance metrics for Puma Biotechnology, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Puma Biotechnology generated $220M in revenue over the last twelve months.
Gross profit for the last twelve months was $167M.
Net income over the last twelve months reached $28.4M.

Fiscal Year Performance

In the most recent fiscal year, Puma Biotechnology reported $230M in total revenue.
Fiscal year EBITDA was $48.1M.
The company maintained a gross profit margin of 72.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 20.9%.
Net profit margin reached 13.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Puma Biotechnology. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Puma Biotechnology Stock Performance

Puma Biotechnology has current market cap of $265M, and EV of $219M.

Market Cap Evolution

Puma Biotechnology Stock Data

As of October 2, 2025, Puma Biotechnology's stock price is $5.

See Puma Biotechnology trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$219M	$265M	XXX	XXX	XXX	XXX	$0.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Puma Biotechnology Valuation Multiples

Puma Biotechnology's trades at 0.9x EV/Revenue multiple, and 4.5x EV/EBITDA.

See valuation multiples for Puma Biotechnology and 15K+ public comps

Puma Biotechnology Financial Valuation Multiples

As of October 2, 2025, Puma Biotechnology has market cap of $265M and EV of $219M.

Equity research analysts estimate Puma Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Puma Biotechnology has a P/E ratio of 9.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$265M	XXX	$265M	XXX	XXX	XXX
EV (current)	$219M	XXX	$219M	XXX	XXX	XXX
EV/Revenue	1.0x	XXX	0.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	4.5x	XXX	XXX	XXX
EV/EBIT	6.7x	XXX	7.1x	XXX	XXX	XXX
EV/Gross Profit	1.3x	XXX	n/a	XXX	XXX	XXX
P/E	9.3x	XXX	8.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	5.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Puma Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Puma Biotechnology Margins & Growth Rates

Puma Biotechnology's last 12 month revenue growth is -1%

Puma Biotechnology's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.8M for the same period.

Puma Biotechnology's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Puma Biotechnology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Puma Biotechnology and other 15K+ public comps

Puma Biotechnology Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-1%	XXX	-3%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	21%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	19%	XXX	20%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	59%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial